Tivozanib - Kyowa Hakko Kirin/AVEO Oncology

Drug Profile

Tivozanib - Kyowa Hakko Kirin/AVEO Oncology

Alternative Names: ASP 4130; AV-951; AVE-951; Fotivda; Kil8951; KRN-951; Tivopath; Tivozanib hydrochloride monohydrate

Latest Information Update: 26 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kirin Brewery
  • Developer Astellas Pharma; AVEO Oncology; EUSA Pharma; Institute Gustave-Roussy; Kyowa Hakko Kirin; Pharmstandard
  • Class Antineoplastics; Isoxazoles; Quinolines; Small molecules; Urea compounds
  • Mechanism of Action Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cell carcinoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Renal cell carcinoma
  • Phase I/II Hepatocellular carcinoma
  • Phase I Solid tumours
  • Suspended Breast cancer; Colorectal cancer; Fallopian tube cancer; Gastrointestinal cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 21 Mar 2018 AVEO Oncology plans to file New drug application (NDA) in North America
  • 21 Mar 2018 Efficacy and safety data from long term follow-up of phase III extension trial in Renal cell carcinoma released by AVEO Oncology
  • 14 Feb 2018 Safety and efficay data from a phase Ib/II in Renal cell carcinoma presented at the 2018 American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO-GU-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top